Helmholtz-zentrum Fur Infektionsforschung Gmbh

Mostafa Hamed

Rolf Wolfgang Hartmann

Heinrich Steinmetz

Klaus Gerth

Rolf Müller

Andreas Kirschning

Jennifer Herrmann

Kathrin Mohr

Franziska Gille

Ritesh Raju

Sascha Baumann

Walid A M Elgaher

Maria Moreno

Liang Liang Wang

Stephan Hüttel

Walid A Elgaher

Stephan Huettel

Christine K Maurer

Jörg Haupenthal

Samir Yahiaoui

Christian Schütz

Martin Empting

Teresa Röhrig

Thomas Hesterkamp

Michael Zender

Ahmed S A Ahmed

Ahmed A M Kamal

Anna K H Hirsch

Andreas M Kany

Stephan Huttel

Walid A M Elhaher

The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for theQuinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially aorinfection.

PqsR inverse agonists

The present invention provides cystobactamides of formula (I): R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;Rand the use thereof for the treatment or prophylaxis of bacterial infections.

Crystobactamides

The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;R&#x2003;&#x2003;(I):

Cystobactamides

The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula. 

Growing community of inventors

Saarbrücken, Germany

Mostafa Hamed